Could the CSL (ASX:CSL) share price hit $325 by the end of 2021?

Where next for the CSL share price?

| More on:
Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has been underperforming in 2021.

Since the start of the year, the biotherapeutics giant's shares have risen just a touch over 1.5% to $289.65.

This compares unfavourably to a 9% gain by the S&P/ASX 200 Index (ASX: XJO) over the same period.

Could the CSL share price hit $325 by the end of 2021?

While the underperformance in the CSL share price has been disappointing, one leading broker appears to see it as an opportunity for investors to buy the shares of a company that would make a great core holding in a portfolio.

According to a recent note out of Morgans, its analysts have an add rating and $324.40 price target on its shares.

Based on the current CSL share price, this implies potential upside of approximately 12% for investors.

As a result, Morgans appears to see potential for the CSL share price to be trading in or around the $325.00 mark come the end of the year.

What did the broker say?

Morgans acknowledges that FY 2022 is going to be a transitional year for the company due to plasma collection headwinds.

It commented: "FY22 guidance is targeting cc NPAT between US$2,150-2,250bn (-9% to -5%) on revenue growth between 2-5%, with management flagging a "transitional year", core plasma products "robust", but margins contracting on increased costs, and Seqirus strength ongoing."

"Plasma collections through FY22 is the key focus and main determinate of margin growth and earnings trajectory into FY23 and beyond, having improved off its nadir (-40%+ last Apr) albeit, not back at pre pandemic levels, on vaccine momentum, CSL initiatives (eg enhanced marketing; new technologies; better donor programs; 40 new collection centres in FY22) and as US COVID stimulus checks ending."

"As such, we view the exact timing of a recovery as uncertain, especially in light of a 9-12 month manufacturing cycle, possibly sticky costs and increasing US restrictions on COVID variants now seen even outside the approaching flu season," it added.

Nevertheless, the broker believes the company is well-positioned for growth once the headwinds ease and remains bullish on the CSL share price.

It concluded: "We view CSL as a core holding and best positioned among its peers to meet growing patient demand, but the near term remains challenged, with timing uncertainty around a full recovery in plasma collections and increasing costs."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Broker looking at the share price.
Broker Notes

3 ASX All Ords shares just got BIG upgrades from top brokers

Leading brokers believe these ASX All Ords stocks could fly higher into 2025.

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A young man wearing a black and white striped t-shirt looks surprised.
Broker Notes

Up 45% in 2024! Can ResMed shares keep rising?

Is this high-flying stock destined to keep soaring? Let's see what one broker is saying.

Read more »

A miner stands in front oh an excavator at a mine site
Broker Notes

Broker says buy the dip on ASX 200 uranium share with 69% upside

Shaw and Partners says this ASX uranium stock is trading at an attractive price point right now.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Broker Notes

Bell Potter says these ASX stocks are top buys

Let's see why the broker is feeling so bullish on these names.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Buy this ASX All Ords stock for huge returns and a great dividend yield

Bell Potter thinks this buy-rated stock could deliver the goods for investors over the next 12 months.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these stocks.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

Top broker says these ASX stocks can rise 35% in a year

Let's see why Bell Potter thinks these shares could rise strongly over the next 12 months.

Read more »